Thus, these results demonstrate that KPT-330 targets XPO1 for degradation to disrupt rRNA and Mcl-1 expression, whereby it primes cancer cells to Bcl-xL inhibitor-induced apoptosis. The gene discussed is BCL2L1; the disease is cancer.